Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates

Press/Media: Press / Media

Period2021 Oct 7

Media coverage

1

Media coverage

  • TitleTurning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date21/10/7
    PersonsSunghoi Hong
View all 1
View less